Innoviva Income Tax Expense vs Reconciled Depreciation Analysis
| INVA Stock | USD 18.99 0.06 0.31% |
Innoviva financial indicator trend analysis is infinitely more than just investigating Innoviva recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Innoviva is a good investment. Please check the relationship between Innoviva Income Tax Expense and its Reconciled Depreciation accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.
Income Tax Expense vs Reconciled Depreciation
Income Tax Expense vs Reconciled Depreciation Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Innoviva Income Tax Expense account and Reconciled Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Innoviva's Income Tax Expense and Reconciled Depreciation is -0.09. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Innoviva, assuming nothing else is changed. The correlation between historical values of Innoviva's Income Tax Expense and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Innoviva are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Income Tax Expense i.e., Innoviva's Income Tax Expense and Reconciled Depreciation go up and down completely randomly.
Correlation Coefficient | -0.09 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Income Tax Expense
Reconciled Depreciation
Most indicators from Innoviva's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Innoviva current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.At present, Innoviva's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 5.50, whereas Discontinued Operations is forecasted to decline to (89.7 M).
Innoviva fundamental ratios Correlations
Click cells to compare fundamentals
Innoviva Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Innoviva fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 724.8M | 999.6M | 926.4M | 1.2B | 1.2B | 1.3B | |
| Total Stockholder Equity | 313.5M | 539.9M | 414.7M | 565.8M | 675.0M | 708.7M | |
| Retained Earnings | (946.4M) | (722.0M) | (456.1M) | (204.9M) | (25.2M) | (26.4M) | |
| Other Assets | 293.6M | 657.5M | 425.2M | 198.5M | 228.2M | 131.6M | |
| Common Stock Shares Outstanding | 113.4M | 113.6M | 94.3M | 95.2M | 86.9M | 81.9M | |
| Liabilities And Stockholders Equity | 724.8M | 999.6M | 926.4M | 1.2B | 1.2B | 1.3B | |
| Other Stockholder Equity | 1.3B | 1.3B | 870.2M | 770.0M | 699.5M | 1.0B | |
| Total Liab | 382.7M | 391.7M | 400.5M | 665.7M | 568.6M | 442.4M | |
| Short Long Term Debt Total | 377.1M | 410.5M | 394.7M | 637.9M | 449.1M | 332.2M | |
| Other Current Liab | 5.4M | 6.0M | 5.7M | 31.7M | 17.2M | 12.9M | |
| Total Current Liabilities | 5.4M | 6.1M | 5.8M | 38.8M | 38.1M | 25.0M | |
| Other Liab | 586K | 219K | 106K | 84.2M | 75.8M | 49.3M | |
| Property Plant And Equipment Net | 33K | 28K | 12K | 3.4M | 3.0M | 2.9M | |
| Net Debt | 99.0M | 139.0M | 193.1M | 346.8M | 255.6M | 192.9M | |
| Accounts Payable | 10K | 66K | 27K | 2.9M | 6.7M | 7.1M | |
| Cash | 278.1M | 246.5M | 201.5M | 291.0M | 193.5M | 138.1M | |
| Non Current Assets Total | 293.6M | 657.5M | 612.7M | 788.0M | 899.3M | 944.3M | |
| Non Currrent Assets Other | 139.4M | 214K | 108K | 101.9M | 87.1M | 68.4M | |
| Long Term Debt | 377.1M | 385.5M | 394.7M | 540.4M | 446.2M | 321.7M | |
| Cash And Short Term Investments | 350.8M | 246.5M | 201.5M | 291.0M | 193.5M | 235.5M | |
| Net Receivables | 79.4M | 93.9M | 110.7M | 64.1M | 84.1M | 88.3M | |
| Common Stock Total Equity | 1.0M | 1.0M | 1.0M | 696K | 800.4K | 857.6K | |
| Short Term Investments | 72.7M | 438.3M | 483.8M | 403.0M | 463.5M | 486.6M | |
| Non Current Liabilities Total | 377.3M | 385.6M | 394.7M | 626.9M | 530.4M | 426.9M | |
| Other Current Assets | 80.4M | 95.6M | 1.4M | 32.5M | 25.9M | 22.6M | |
| Property Plant And Equipment Gross | 33K | 28K | 12K | 3.4M | 3.0M | 2.9M | |
| Total Current Assets | 431.2M | 342.1M | 313.7M | 443.5M | 344.2M | 281.5M | |
| Common Stock | 1.0M | 1.0M | 696K | 692K | 633K | 845.9K | |
| Property Plant Equipment | 33K | 28K | 12K | 3.4M | 3.1M | 2.9M | |
| Inventory | (79.4M) | (93.9M) | (110.7M) | 55.9M | 40.7M | 42.8M | |
| Net Tangible Assets | 313.5M | 539.9M | 414.7M | 286.2M | 329.1M | 345.5M | |
| Noncontrolling Interest In Consolidated Entity | 152K | 5.5M | 67.9M | 111.2M | 127.9M | 134.3M | |
| Retained Earnings Total Equity | (1.5B) | (1.1B) | (722.0M) | (456.1M) | (524.6M) | (550.8M) | |
| Long Term Debt Total | 574.4M | 382.9M | 377.1M | 385.5M | 443.3M | 463.7M | |
| Capital Surpluse | 1.3B | 1.3B | 1.3B | 1.3B | 1.1B | 1.1B | |
| Deferred Long Term Liab | 139.1M | 125.3M | 111.4M | 97.6M | 112.2M | 122.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Innoviva offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Innoviva's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Innoviva Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Innoviva Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.98) | Earnings Share 0.8 | Revenue Per Share 5.6 | Quarterly Revenue Growth 0.331 | Return On Assets 0.0937 |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.